Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
19.78
+1.08 (5.78%)
At close: Apr 17, 2026, 4:00 PM EDT
19.95
+0.17 (0.84%)
After-hours: Apr 17, 2026, 7:48 PM EDT
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Monte Rosa Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $32, which forecasts a 61.78% increase in the stock price over the next year. The lowest target is $29 and the highest is $37.
Price Target: $32 (+61.78%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 18, 2026.
Analyst Ratings
The average analyst rating for Monte Rosa Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 1 | 2 | 3 | 3 | 3 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $34 → $30 | Strong Buy | Maintains | $34 → $30 | +51.67% | Mar 18, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $30 → $29 | Buy | Maintains | $30 → $29 | +46.61% | Mar 18, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $28 → $37 | Buy | Reiterates | $28 → $37 | +87.06% | Jan 14, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $30 | Buy | Maintains | $22 → $30 | +51.67% | Jan 8, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $16 → $34 | Strong Buy | Maintains | $16 → $34 | +71.89% | Jan 8, 2026 |
Financial Forecast
Revenue This Year
57.90M
from 123.67M
Decreased by -53.18%
Revenue Next Year
59.32M
from 57.90M
Increased by 2.45%
EPS This Year
-1.68
from -0.46
EPS Next Year
-1.77
from -1.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 200.6M | 300.3M | |||
| Avg | 57.9M | 59.3M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 62.2% | 418.6% | |||
| Avg | -53.2% | 2.4% | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.04 | 0.61 | |||
| Avg | -1.68 | -1.77 | |||
| Low | -2.13 | -2.82 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.